Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Assets (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Assets for 15 consecutive years, with $3.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Assets rose 4.9% year-over-year to $3.7 million, compared with a TTM value of $3.7 million through Sep 2025, up 4.9%, and an annual FY2024 reading of $2.8 million, down 66.66% over the prior year.
  • Assets was $3.7 million for Q3 2025 at Alaunos Therapeutics, down from $4.7 million in the prior quarter.
  • Across five years, Assets topped out at $128.5 million in Q1 2021 and bottomed at $2.1 million in Q1 2025.
  • Average Assets over 5 years is $45.6 million, with a median of $27.9 million recorded in 2023.
  • The sharpest move saw Assets crashed 87.59% in 2024, then rose 4.9% in 2025.
  • Year by year, Assets stood at $94.9 million in 2021, then tumbled by 31.55% to $64.9 million in 2022, then plummeted by 87.28% to $8.3 million in 2023, then plummeted by 66.66% to $2.8 million in 2024, then skyrocketed by 35.17% to $3.7 million in 2025.
  • Business Quant data shows Assets for TCRT at $3.7 million in Q3 2025, $4.7 million in Q2 2025, and $2.1 million in Q1 2025.